(Q34667588)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25604710%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

review article

1 reference

title

Delafloxacin for the treatment of respiratory and skin infections (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25604710%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

main subject

delafloxacin

0 references

Respiratory Infections

0 references

author

Elda Righi

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25604710%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1

Matteo Bassetti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25604710%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

4

Claudio Scarparo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25604710%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Paola Della Siega

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25604710%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Davide Pecori

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25604710%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

21 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25604710%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25604710%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25604710%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25604710%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

433-442

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25604710%20AND%20SRC:MED&resulttype=core&format=json

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Unmet medical need in infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

New uses for new and old quinolones and the challenge of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Systematic review: fluoroquinolones for the treatment of intra-abdominal surgical infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Global fluoroquinolone resistance epidemiology and implictions for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.1005205

10.1517/13543784.2015.1005205

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25604710%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference